Medical Doctor Program year 2025 Source: CMS Open Payments, 2026 publication

Vinesh Kumar

Hospitalist Murray, UT Medical Doctor

NPI 1669114641 CMS profile 11895266

5121 S Cottonwood St, Murray, UT 84107

Open in the dashboard

General payments

$650

10 records reported · program year 2025

Research payments

$0

Paid to them · None reported · program year 2025

Ownership & investment interest

$0

None reported

Through program year 2025, Vinesh Kumar of Murray, UT is reported in the CMS Open Payments database as having received $650 across 10 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Hospitalist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2025 General $650 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vinesh Kumar
  • Hospitalist median
  • Middle half of Hospitalist
  • National median

In program year 2025, general payments to Vinesh Kumar were reported at $650. Among 6,882 Hospitalist profiles paid that year, the median was $86 and the middle half received between $30 and $191.

Show as a table
Year Vinesh Kumar Hospitalist median Middle half National median
2019 $0 $96 $28–$201 $163
2020 $0 $48 $19–$125 $114
2021 $0 $70 $23–$167 $132
2022 $0 $85 $27–$174 $149
2023 $0 $89 $30–$191 $160
2024 $0 $95 $29–$204 $164
2025 $650 $86 $30–$191 $169

Breakdown

Who paid General payments · program year 2025
  1. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $442 6 payments
  2. Dexcom, Inc. $145 1 payment
  3. Novo Nordisk Inc $39 2 payments
  4. Grifols USA, LLC $24 1 payment

Every payment, record by record

What the payments were for General payments · program year 2025
  1. Food and Beverage $650 10 payments
Products named General payments · program year 2025
  1. LifeVest $442 6 payments
  2. DEXCOM G7 GSS (161) $145 1 payment
  3. DEXCOM STELO GLUCOSE BIOSENSOR $145 1 payment
  4. Prolastin-C Liquid $24 1 payment
  5. Ozempic $19 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

17

Median for Hospitalist: 109

Drug cost

$80

Median for Hospitalist: $6,399

Branded share of claims

0%

Median for Hospitalist: 19.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Atorvastatin Calcium Generic 17 $80

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,498 Part D prescribers listed as Hospitalist; they describe a distribution and say nothing about conduct.

Records

10 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record